摘要
目的：评价Ⅲ期非小细胞肺癌（NSCLC）切除术后辅助化疗疗效,并对影响术后辅助化疗的因素进行初步分析.方法：回顾性分析本院268例切除术后的Ⅲ期NSCLC,有94例于术后3～4周开始接受化疗（辅助化疗组）,其中予以CAP方案化疗42例;EP方案化疗34例;NP方案化疗18例.在化疗组中化疗3～4周期56例;化疗4～6周期38例.另174例患者术后未行化疗（单纯手术组）.结果：辅助化疗组和单纯手术组的5年生存率分别为27.6%和16.6%（P＜0.05）,差别有统计学意义.在辅助化疗组中行CAP、EP、NP方案化疗组的5年生存率分别为26.1%、26.4%和27.7%（P＞0.05）,而在化疗组中化疗3～4周期和化疗5～6周期患者的5年生存率分别为26.7%和28.8%（P＞0.05）.结论：对切除术后Ⅲ期NSCLC患者进行3～4周期,以顺铂为基础的化疗方案的辅助化疗,可以提高长期生存率.
Objective：To evaluate the effect of adjuvant chemotherapy after radical surgery for stage m non-small cell lung cancer（NSCLC） and analyze the factor that influence the adjuvant chemotherapy. Methods ：We analysed clinical data in 268 cases of stage Ⅲ NSCLC undergone resectional surgery. 94 patients received adjuvant chemotherapy after undergone radical surgery （adjuvant chemotherapy group）. 174 patients received surgery alone（ surgery group）. In adjuvant chemotherapy group, 42 patients received adjuvant chemotherapy with CAP regimen,34 patients with EP and 18 patients with NP. In adjuvant chemotherapy group, 56 patients received adjuvant chemotherapy for 3 or 4 cycles and 38 patients for 5 or 6 cycles. Results ：The 5-year survival rate was 27.6% in the adjuvant chemotherapy group and 16.6% in the surgery group. There was significant discrepancy （P 〉 0. 05 ）. The 5-year survival in CAP, EP and NP group were 26. 1% ,26. 6% and 27. 7% respectively, there was no significant discrepancy（P 〉 0. 05 ）. The 5-year survival in 3 or 4 cycles patients were 26. 7% and the 5-year survival in 5 or 6 cycles patients were 28. 9% . there was no significant discrepancy（P〉0. 05）. Conclusion：Postoperative adjuvant chemotherapy with platinum-based regimen for 3 or 4 cycles can improve survival rate for stage Ⅲ NSCLC patients.
出处
《临床肿瘤学杂志》
CAS
2006年第3期173-175,共3页
Chinese Clinical Oncology
关键词
非小细胞肺癌
外科治疗
辅助化疗
生存率
Non-small-cell lung cancer
Surgery
Adjuvant chemotherapy
Survival rate
